Fagron (FAGR) CMD 2025 summary

Strategic direction and market outlook

• Targets high single- to low double-digit organic revenue CAGR at constant FX through 2030, with a focus on operational excellence, innovation, and disciplined M&A.

• Four strategic enablers: quality focus, global operational excellence, specialized R&D, and disciplined M&A, supporting leadership in Essentials, Brands, sterile outsourcing, and legacy business optimization.

• Market for personalized medicine expected to grow from $13.2 billion to $18 billion over five years, driven by aging populations, increased regulation, and drug shortages.

• Expansion into Asia-Pacific and further consolidation in EMEA and North America are key growth priorities, with APAC entry prioritized via partnerships and joint ventures.

• Strategy supported by targeted investments, disciplined capital allocation, and a globally aligned leadership team.

Financial performance and guidance

• Achieved over 9% organic growth (2022–2024), surpassing the 8% target, with EBITDA reaching $174 million and a 20% margin.

• Aims for REBITDA margin of approximately 21% by 2027, with further progressive increases through 2030.

• Free cash flow conversion expected to be at least 50%, operating cash flow conversion at least 70%, and capex at 3.5% of revenue.

• Sets mid-term net debt to EBITDA target of 2.8x, with a maximum leverage of 3.5x.

• 2025 guidance reiterates mid to high single-digit organic growth, with a step up in profitability and CapEx around 3.5% (excluding one-offs).

Regional and business segment outlook

• North America expected to drive growth with low- to mid-teens CAGR, EMEA at mid-single digits, and Latin America at high-single digits.

• Compounding Services projected to outpace Brands & Essentials (B&E) growth; Brands to grow faster than Essentials.

• APAC entry prioritized via partnerships and joint ventures, targeting 4% CAGR and €2.5bn market size by 2030.

• Margin expansion to be driven by operational excellence, global Brands strategy, and operating leverage.

• M&A remains a key value creation lever, focusing on market consolidation, product capabilities, and geographic expansion.